Two investigational Ebola treatments being used in the ongoing outbreak in the Democratic Republic of the Congo are effective in laboratory studies, according to new Centers for Disease Control and Prevention research. The treatments — the antiviral remdesivir and antibodies in the ZMapp treatment — blocked growth of the virus strain causing the outbreak in human cells in the laboratory. The research suggests these treatments hold promise for allowing patients to recover from the deadly illness. The research was published yesterday in Lancet Infectious Diseases. The study also shows that the lab test most often used in the DRC and neighboring countries to diagnose Ebola — which was developed during the 2014-2016 West Africa outbreak for use against a different strain of Ebola virus — appears to be accurate for the outbreak strain now circulating in DRC.

Related News Articles

Headline
The Department of Health and Human Services and the Centers for Medicare & Medicaid Services Aug. 21 announced the creation of a Healthcare Advisory…
Headline
The American Heart Association and American College of Cardiology Aug. 14 released new guidelines on high blood pressure prevention, suggesting earlier…
Headline
Josh Neff, CEO of CommonSpirit Mercy Hospital, discusses a new cutting-edge communication platform that sends patient EKGs directly from the ambulance to the…
Headline
A JAMA study published yesterday found that more adults age 45-49 have been diagnosed with colorectal cancer, a finding that coincides with recommendations by…
Headline
A study published June 25 by the Journal of the American Heart Association found that heart disease death rates fell 66% from 1970 to 2022. Deaths from heart…
Headline
The White House May 22 released its Make America Healthy Again report that focuses on childhood chronic disease. The report highlights findings from the MAHA…